Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press10310.17650/2313-805X-2017-4-3-67-74RESEARCH ARTICLESЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИThe transforming growth factor beta-1 in the oncogenesis of human lung adenocarcinomaТрансформирующий фактор роста бета-1 в онкогенезе аденокарциномы легкого человекаShevchenkoV. E.ШевченкоВ. Е.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

vshev2015@yandex.ruBryukhovetskiyI. S.БрюховецкийИ. С.
Russian Federation

17 Pal’chevskogo St., Vladivostok 690059.

690059 Владивосток, ул. Пальчевского, 17.

NikiforovaZ. N.НикифороваЗ. Н.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

KovalevS. V.КовалевС. В.
Russian Federation

GSP-1, Build. 3, 1 Leninskie Gory, Moscow 119991

119991 Москва, Ленинские горы, 1, стр. 3, ГСП-1

KudryavtsevI. A.КудрявцевИ. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

ArnotskayaN. E.АрноцкаяН. Е.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia.НИИ канцерогенеза ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России.Biomedicine School, Far Eastern Federal UniversityШкола биомедицины ФГАОУ ВПО «Дальневосточный федеральный университет»National Scientific Center of Marine Biology, Far Eastern Brach, Russian Academy of Sciences.ФГБУН «Национальный научный центр морской биологии» Дальневосточного отделения РАН.Department of Chemistry, M.V. Lomonosov Moscow State University.Химический факультет ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова.150920174367741610201716102017Copyright ©; 2017, Shevchenko V.E., Bryukhovetskiy I.S., Nikiforova Z.N., Kovalev S.V., Kudryavtsev I.A., Arnotskaya N.E.Copyright ©; 2017, Шевченко В.Е., Брюховецкий И.С., Никифорова З.Н., Ковалев С.В., Кудрявцев И.А., Арноцкая Н.Е.2017Shevchenko V.E., Bryukhovetskiy I.S., Nikiforova Z.N., Kovalev S.V., Kudryavtsev I.A., Arnotskaya N.E.Шевченко В.Е., Брюховецкий И.С., Никифорова З.Н., Ковалев С.В., Кудрявцев И.А., Арноцкая Н.Е.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/103

Background. The transforming growth factor beta 1 (TGF-β1) is one of the most important tissue factors secreted by the development of epithelial tumors. Increased expression of TGF-β1 in lung tumors promotes cancer cells survival enhancing their growth, migration, invasion, angiogenesis, immune system suppression.

Objective: to study molecular mechanisms of TGF-β1 action on A549 human lung adenocarcinoma cells by means of proteomic high-resolution mass spectrometry. Results. Intracellular signaling pathways responsible for the involvement of TGF-β1 in the oncogenesis of non-small cell lung cancer have been found, which include the differential expressed proteins of the families of cullin, ETS oncogenes, histone diacelases, cyclin-dependent kinases, and the signaling pathway phosphatidylinositol 3-kinase (PI3K).

Conclusions. Important patterns are determined that could be used for the development of new approaches for detection of lung cancer metastasis candidate markers and potential therapy targets of this decease.

transforming growth factor beta 1lung adenocarcinomaproteomemass-spectrometryepithelial-mesenchymal transitionтрансформирующий фактор роста бета-1аденокарцинома легкогопротеоммасс-спектрометрияэпителиальномезенхимальный переход1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CACancer J Clin 2012;62(1):10–29.Siegel R., Naishadham D., Jemal A. Cancer statistics. CACancer J Clin 2012;62(1):10–29.2. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64(2):327–36.Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64(2):327–36.3. Ganti A.K., Huang C.H., Klein M.A. et al. Lung cancer management in 2010. Oncology (Williston Park) 2011;25(1): 64–73.Ganti A.K., Huang C.H., Klein M.A. et al. Lung cancer management in 2010. Oncology (Williston Park) 2011;25(1): 64–73.4. Kojima Y., Acar A., Eaton E.N. et al. Autocrine TGF-beta and stromal cellderived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 2010;107(46): 20009–14.Kojima Y., Acar A., Eaton E.N. et al. Autocrine TGF-beta and stromal cellderived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 2010;107(46): 20009–14.5. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Inves 2009;119(6):1420–8.Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Inves 2009;119(6):1420–8.6. Morel A.P., Lievre M., Thomas C. et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3(8):e2888.Morel A.P., Lievre M., Thomas C. et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3(8):e2888.7. Miyazono K., Ehata S., Koinuma D. Tumor-promoting functions of transforming growth factor-β in progression of cancer. Ups J Med Sci 2012;117(2):143–52.Miyazono K., Ehata S., Koinuma D. Tumor-promoting functions of transforming growth factor-β in progression of cancer. Ups J Med Sci 2012;117(2):143–52.8. Ikushima H., Todo T., Ino Y. et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009;5(5):504–14.Ikushima H., Todo T., Ino Y. et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009;5(5):504–14.9. Zhao L., Ji W., Zhang L. et al. Changes of circulating transforming growth factorbeta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer. J Thorac Oncol 2010;5(4):521–5.Zhao L., Ji W., Zhang L. et al. Changes of circulating transforming growth factorbeta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer. J Thorac Oncol 2010;5(4):521–5.10. Dancea H.C., Shareef M.M., Ahmed M.M. Role of radiation-induced TGF-beta signaling in cancer therapy. Mol Cell Pharmacol 2009;1(1):44–56.Dancea H.C., Shareef M.M., Ahmed M.M. Role of radiation-induced TGF-beta signaling in cancer therapy. Mol Cell Pharmacol 2009;1(1):44–56.11. Rahimi R.A., Leof E.B. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007;102(3):593–608.Rahimi R.A., Leof E.B. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007;102(3):593–608.12. Шевченко В.Е., Ковалев С.В., Арноцкая Н.Е. и др. Молекулярные детерминанты действия трансформирующего фактора роста бета-1 на клетки глиобластомы человека. Успехи молекулярной онкологии 2016;3(2):50–9. [Shevchenko V.E., Kovalev S.V., Arnotskaya N.E. et al. Molecular determinants of transforming growth factor beta-1 action on human glioblastoma cells. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2016;3(2):50–9. (In Russ.)].Шевченко В.Е., Ковалев С.В., Арноцкая Н.Е. и др. Молекулярные детерминанты действия трансформирующего фактора роста бета-1 на клетки глиобластомы человека. Успехи молекулярной онкологии 2016;3(2):50–9. [Shevchenko V.E., Kovalev S.V., Arnotskaya N.E. et al. Molecular determinants of transforming growth factor beta-1 action on human glioblastoma cells. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2016;3(2):50–9. (In Russ.)].13. Derynck R., Akhurst R.J., Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29(2):117–29.Derynck R., Akhurst R.J., Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29(2):117–29.14. Elliott R.L., Blobe G.C. Role of transforming growth factor b in human cancer. J Clin Oncol 2005;23:2078–93.Elliott R.L., Blobe G.C. Role of transforming growth factor b in human cancer. J Clin Oncol 2005;23:2078–93.15. Padua D., Massague J. Roles of TGF-β in metastasis. Cell Res 2009;19:89–102.Padua D., Massague J. Roles of TGF-β in metastasis. Cell Res 2009;19:89–102.16. Jakowlew S.B. Transforming growth factor-β in lung cancer, carcinogenesis, and metastasis. In: The tumor microenvironment. Ed. R.G. Bagley. 2010. Рр. 633–671.Jakowlew S.B. Transforming growth factor-β in lung cancer, carcinogenesis, and metastasis. In: The tumor microenvironment. Ed. R.G. Bagley. 2010. Рр. 633–671.17. Ma C., Rong Y., Radiloff D.R. et al. Extracellular matrix protein big-h3/ TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 2008;22(3):308–21.Ma C., Rong Y., Radiloff D.R. et al. Extracellular matrix protein big-h3/ TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 2008;22(3):308–21.18. Giampieri S., Manning C., Hooper S. et al. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009;11(11):1287–96.Giampieri S., Manning C., Hooper S. et al. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009;11(11):1287–96.19. Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymallike transition and promotes metastasis. Cancer Cell 2011;20(5):576–90.Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymallike transition and promotes metastasis. Cancer Cell 2011;20(5):576–90.20. Yuan J.H., Yang F., Wang X. et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014;25(5):666–81.Yuan J.H., Yang F., Wang X. et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014;25(5):666–81.21. Hasegawa Y., Takanashi S., Kanehira Y. et al. Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001;91(5):964–71.Hasegawa Y., Takanashi S., Kanehira Y. et al. Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001;91(5):964–71.22. Toonkel R.L., Borczuk A.C., Powell C.A. TGF-β signaling pathway in lung adenocarcinoma invasion. J Thorac Oncol 2010;5(2):153–7.Toonkel R.L., Borczuk A.C., Powell C.A. TGF-β signaling pathway in lung adenocarcinoma invasion. J Thorac Oncol 2010;5(2):153–7.23. Vazquez P.F., Carlini M.J., Daroqui M.C. et al. TGF-β specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer. Clin Exp Metastasis 2013;30(8):993–1007.Vazquez P.F., Carlini M.J., Daroqui M.C. et al. TGF-β specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer. Clin Exp Metastasis 2013;30(8):993–1007.24. Massague J. TGF-β signalling in context. Nat Rev Mol Cell Biol 2012;13(10): 616–30.Massague J. TGF-β signalling in context. Nat Rev Mol Cell Biol 2012;13(10): 616–30.25. Michl P., Ramjaun A.R., Pardo O.E. et al. CUTL1 is a target of TGF-β signaling that enhances cancer cell motility and invasiveness. Cancer Cell 2005;7(6): 521–32.Michl P., Ramjaun A.R., Pardo O.E. et al. CUTL1 is a target of TGF-β signaling that enhances cancer cell motility and invasiveness. Cancer Cell 2005;7(6): 521–32.26. Gregory P.A., Bracken C.P., Smith E. et al. An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelialmesenchymal transition. Mol Biol Cell 2011;22(10):1686–98.Gregory P.A., Bracken C.P., Smith E. et al. An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelialmesenchymal transition. Mol Biol Cell 2011;22(10):1686–98.27. Shibue T., Brooks M.W., Weinberg R.A. An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell 2013;24(4):481–98.Shibue T., Brooks M.W., Weinberg R.A. An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell 2013;24(4):481–98.28. Genschik P., Sumara I., Lechner E. The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications. EMBO J 2013;32(17):2307–20.Genschik P., Sumara I., Lechner E. The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications. EMBO J 2013;32(17):2307–20.29. Linehan W.M., Lerman M.I., Zbar B. Identification of the von Hippel–Lindau (VHL) gene. Its role in renal cancer. JAMA 1995;273:564–70.Linehan W.M., Lerman M.I., Zbar B. Identification of the von Hippel–Lindau (VHL) gene. Its role in renal cancer. JAMA 1995;273:564–70.30. Chen H.Y., Chen R.H. Cullin 3 ubiquitin ligases in cancer biology: functions and therapeutic implications. Front Oncol 2016;6:113.Chen H.Y., Chen R.H. Cullin 3 ubiquitin ligases in cancer biology: functions and therapeutic implications. Front Oncol 2016;6:113.31. Laudet V., Hänni C., Stéhelin D. Molecular phylogeny of the ETS gene family. Oncogene 1999;18(6):1351–9.Laudet V., Hänni C., Stéhelin D. Molecular phylogeny of the ETS gene family. Oncogene 1999;18(6):1351–9.32. Sementchenko V.I., Watson D.K. Ets target genes: past, present and future. Oncogene 2000;19(55):6533–48.Sementchenko V.I., Watson D.K. Ets target genes: past, present and future. Oncogene 2000;19(55):6533–48.33. Fujimoto J., Aoki I., Toyoki H. et al. Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology 2004;66(5):420–8.Fujimoto J., Aoki I., Toyoki H. et al. Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology 2004;66(5):420–8.34. Yamaguchi E., Nakayama T., Nanashima A. et al. Ets-1 proto-oncogene as a potential predictor for poor prognosis of lung adenocarcinoma. Tohoku J Exp Med 2007;213(1):41–50.Yamaguchi E., Nakayama T., Nanashima A. et al. Ets-1 proto-oncogene as a potential predictor for poor prognosis of lung adenocarcinoma. Tohoku J Exp Med 2007;213(1):41–50.35. Rothhammer T., Hahne J.C., Florin C. et al. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci 2004;61(1):118–28.Rothhammer T., Hahne J.C., Florin C. et al. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci 2004;61(1):118–28.36. Nakayama T., Ito M., Ohtsuru A. et al. Expression of the Ets-1 proto-oncogene in human colorectal carcinoma. Mod Pathol 2001;14(5):415–22.Nakayama T., Ito M., Ohtsuru A. et al. Expression of the Ets-1 proto-oncogene in human colorectal carcinoma. Mod Pathol 2001;14(5):415–22.37. Span P.N., Manders P., Heuvel J.J. et al. Expression of the transcription factor Ets1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002;21(55):8506–9.Span P.N., Manders P., Heuvel J.J. et al. Expression of the transcription factor Ets1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002;21(55):8506–9.38. Puzovic V., Brcic I., Ranogajec I., JakicRazumovic J. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and coexpression in breast cancer patients. Neoplasma 2014;61(4):439–46.Puzovic V., Brcic I., Ranogajec I., JakicRazumovic J. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and coexpression in breast cancer patients. Neoplasma 2014;61(4):439–46.39. Hahne J.C., Okuducu A.F., Kaminski A. et al. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchoragein-dependent growth. Oncogene 2005;24(34):5384–8.Hahne J.C., Okuducu A.F., Kaminski A. et al. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchoragein-dependent growth. Oncogene 2005;24(34):5384–8.40. Stamatkin C., Ratermann K.L., Overley C.W. et al. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. Cancer Biol Ther 2015;16(9):1341–52.Stamatkin C., Ratermann K.L., Overley C.W. et al. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. Cancer Biol Ther 2015;16(9):1341–52.41. Sui X., Zhu J., Zhou J. et al. Epigenetic modifications as regulatory elements of autophagy in cancer. Cancer Lett 2015;360(2):106–13.Sui X., Zhu J., Zhou J. et al. Epigenetic modifications as regulatory elements of autophagy in cancer. Cancer Lett 2015;360(2):106–13.42. Rodrigues M.F., Carvalho É., Pezzuto P. et al. Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin a on the energy metabolism of breast cancer cells. J Cell Biochem 2015;116(5):797–808.Rodrigues M.F., Carvalho É., Pezzuto P. et al. Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin a on the energy metabolism of breast cancer cells. J Cell Biochem 2015;116(5):797–808.43. Song J., Noh J.H., Lee J.H. et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005;113(4):264–8.Song J., Noh J.H., Lee J.H. et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005;113(4):264–8.44. Brock M.V., Hooker C.M., Ota-Machida E. et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358(11):1118–28.Brock M.V., Hooker C.M., Ota-Machida E. et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358(11):1118–28.45. Sterlacci W., Tzankov A., Veits L. et al. A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J Thorac Oncol 2011;6(10):1649–57.Sterlacci W., Tzankov A., Veits L. et al. A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J Thorac Oncol 2011;6(10):1649–57.46. Ibanez de Caceres I., Cortes-Sempere M., Moratilla C. et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-smallcell lung cancer. Oncogene 2010;29(11):1681–90.Ibanez de Caceres I., Cortes-Sempere M., Moratilla C. et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-smallcell lung cancer. Oncogene 2010;29(11):1681–90.47. Kaimori A., Potter J.J., Choti M. et al. Histone deacetylase inhibition suppresses the transforming growth factor beta1induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology 2010;52(3):1033–45.Kaimori A., Potter J.J., Choti M. et al. Histone deacetylase inhibition suppresses the transforming growth factor beta1induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology 2010;52(3):1033–45.48. Chung C.L., Sheu J.R, Chen W.L. et al. Histone deacetylase inhibitor mcarboxycinnamic acid bis-hydroxamide attenuates plasminogen activator inhibitor-1 expression in human pleural mesothelial cells. Am J Respir Cell Mol Biol 2012;46(4):437–45.Chung C.L., Sheu J.R, Chen W.L. et al. Histone deacetylase inhibitor mcarboxycinnamic acid bis-hydroxamide attenuates plasminogen activator inhibitor-1 expression in human pleural mesothelial cells. Am J Respir Cell Mol Biol 2012;46(4):437–45.49. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74.Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74.50. Ortega S., Malumbres M., Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602(1):73–87.Ortega S., Malumbres M., Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602(1):73–87.51. Choi Y.J., Li X., Hydbring P. et al. The requirement for cyclin d function in tumor maintenance. Cancer Cell 2012;22(4):438–51.Choi Y.J., Li X., Hydbring P. et al. The requirement for cyclin d function in tumor maintenance. Cancer Cell 2012;22(4):438–51.52. Schutte M., Hruban R.H., Hedrick L. et al. DPC4 gene in various tumor types. Cancer Res 1996;56(11):2527–30.Schutte M., Hruban R.H., Hedrick L. et al. DPC4 gene in various tumor types. Cancer Res 1996;56(11):2527–30.53. Aso T., Lane W.S., Conaway J.W., Conaway R.C. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 1995;269(5229):1439–43.Aso T., Lane W.S., Conaway J.W., Conaway R.C. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 1995;269(5229):1439–43.54. Cockman M.E., Masson N., Mole D.R. et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel–Lindau tumor suppressor protein. J Biol Chem 2000;275(33):25733–41.Cockman M.E., Masson N., Mole D.R. et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel–Lindau tumor suppressor protein. J Biol Chem 2000;275(33):25733–41.55. Jalava S.E., Porkka K.P., Rauhala H.E. et al. TCEB1 promotes invasion of prostate cancer cells. Int J Cancer 2009;124(1): 95–102.Jalava S.E., Porkka K.P., Rauhala H.E. et al. TCEB1 promotes invasion of prostate cancer cells. Int J Cancer 2009;124(1): 95–102.56. Zhao X., Chen M., Tan J. Knockdown of ZFR suppresses cell proliferation and invasion of human pancreatic cancer. Biol Res 2016;49(1):26.Zhao X., Chen M., Tan J. Knockdown of ZFR suppresses cell proliferation and invasion of human pancreatic cancer. Biol Res 2016;49(1):26.57. Lim Y.S., Tang B.L. The Evi5 family in cellular physiology and pathology. FEBS Lett. 2013; 587(12):1703–10.Lim Y.S., Tang B.L. The Evi5 family in cellular physiology and pathology. FEBS Lett. 2013; 587(12):1703–10.